Vir Biotechnology (VIR) AI Stock Analysis

• Market Cap: $729.31M
• Dividend Yield: N/A
• Average Volume (3M): 1.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: -78.55%
• EPS Growth: 7.74%
• Country: US
• Employees: 408
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.17
• Shares Outstanding: 138,916,430
• 10 Day Avg. Volume: 1,678,599
• 30 Day Avg. Volume: 1,461,106
• PEG Ratio: 0.12
• Price to Book (P/B): 0.87
• Price to Sales (P/S): 13.48
• P/FCF Ratio: -2.20
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $15.00
• Price Target Upside: 192.97% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $5.00 ▼(-2.34% Downside)

Vir Biotechnology's overall stock score is primarily impacted by its financial performance, which is currently weak due to declining revenues and profitability issues. The technical analysis and valuation also present challenges, with bearish indicators and a negative P/E ratio. The earnings call provides some optimism with progress in clinical programs, but financial losses and high R&D expenses remain significant hurdles. The company's ability to stabilize and grow revenues through strategic initiatives will be crucial for future improvement.

Positive Factors

Strong Cash Position

A strong cash position provides financial stability and flexibility, enabling continued investment in R&D and strategic initiatives without immediate funding pressures.

Progress in Clinical Programs

Timely progress in clinical trials enhances the potential for future regulatory approvals and commercialization, strengthening the company's pipeline and market position.

R&D Efficiency

Improved R&D efficiency through cost savings enhances the company's ability to allocate resources effectively, supporting long-term innovation and profitability.

Negative Factors

Negative Revenue Growth

Negative revenue growth and profitability issues can hinder sustainable business operations, limiting the company's ability to invest in future growth opportunities.

High R&D Expenses

High R&D expenses, while necessary for innovation, can strain financial resources and impact short-term profitability, requiring careful management to ensure long-term success.

Dependence on Future Data

Reliance on future clinical data introduces uncertainty, as any setbacks could delay product development and affect the company's growth trajectory and market expectations.

Vir Biotechnology Business Overview & Revenue Model

Company Description

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on treating and preventing serious infectious diseases. The company leverages its proprietary technology platforms, including monoclonal antibodies and T cell therapies, to develop innovative solutions against viral infections such as COVID-19, influenza, and hepatitis B. Vir's core products include investigational therapies aimed at harnessing the immune system to combat these diseases, with a strong emphasis on scientific research and development.

How the Company Makes Money

Vir Biotechnology generates revenue primarily through the development and commercialization of its therapeutic products. This includes income from partnerships and collaborations with larger pharmaceutical companies, which often provide upfront payments, milestone payments, and royalties on sales. The company has entered into significant agreements aimed at accelerating the development and distribution of its therapies, particularly in response to public health needs, such as its collaboration with GlaxoSmithKline for the development of COVID-19 treatments. Additionally, government contracts and grants related to pandemic response initiatives can contribute to revenue, alongside potential market sales of approved therapies once they reach commercialization.

Vir Biotechnology Financial Statement Overview

Summary

Vir Biotechnology faces significant financial challenges, particularly in terms of profitability and cash flow management. Despite a strong gross profit margin and low leverage, negative revenue growth and substantial operating losses pose risks. The balance sheet remains relatively stable, but the company needs to address its profitability issues to improve its financial health.

Income Statement

Vir Biotechnology's income statement shows significant challenges. The company has experienced negative revenue growth in recent periods, with a TTM revenue decline of 10.05%. Profitability metrics are concerning, with a negative net profit margin of -33.02% and EBIT margin of -35.87% in the TTM. Despite a strong gross profit margin of 95.53%, the company struggles with high operating losses.

Balance Sheet

The balance sheet reflects moderate stability with a low debt-to-equity ratio of 0.10 in the TTM, indicating low leverage. However, the return on equity is negative at -50.22%, highlighting profitability issues. The equity ratio is not explicitly calculated, but the company maintains a substantial equity base relative to its assets.

Cash Flow

Cash flow analysis reveals a challenging situation with negative operating cash flow and free cash flow in the TTM. However, the free cash flow to net income ratio is slightly positive at 1.02, suggesting some efficiency in cash management despite losses. Free cash flow growth is positive at 10.48%, indicating some improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.53M	74.20M	86.18M	1.58B	1.09B	67.25M
Gross Profit	-83.69M	73.36M	83.42M	1.43B	1.02B	-234.33M
EBITDA	-542.61M	-537.61M	-664.85M	833.07M	420.75M	-289.80M
Net Income	-499.65M	-521.96M	-615.06M	515.84M	528.58M	-298.67M
Balance Sheet
Total Assets	1.02B	1.40B	1.92B	2.80B	1.95B	918.76M
Cash, Cash Equivalents and Short-Term Investments	500.05M	905.35M	1.52B	2.40B	708.14M	736.86M
Total Debt	91.22M	97.89M	124.54M	127.97M	133.56M	66.56M
Total Liabilities	223.35M	248.43M	328.82M	724.13M	522.42M	201.91M
Stockholders Equity	796.10M	1.15B	1.59B	2.08B	1.43B	716.85M
Cash Flow
Free Cash Flow	-455.95M	-453.65M	-800.36M	1.60B	-69.41M	-197.49M
Operating Cash Flow	-453.54M	-446.35M	-778.78M	1.66B	-47.59M	-190.94M
Investing Cash Flow	364.46M	499.37M	164.63M	-1.19B	-140.81M	-9.86M
Financing Cash Flow	4.01M	4.39M	7.48M	34.76M	100.33M	529.47M

Vir Biotechnology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIR, the sentiment is Negative. The current price of 5.12 is below the 20-day moving average (MA) of 5.86, below the 50-day MA of 5.54, and below the 200-day MA of 6.12, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.18 is Neutral, neither overbought nor oversold. The STOCH value of 10.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VIR.

Vir Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$641.63M	―	-43.63%	―	―	-13.05%
XNCR	54 Neutral	$1.02B	-7.88	-19.61%	―	38.16%	48.43%
SEPN	52 Neutral	$867.63M	―	-32.78%	―	-13.37%	-1025.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IOVA	45 Neutral	$658.57M	―	-53.16%	―	636.99%	27.10%
VIR	42 Neutral	$729.31M	―	-49.06%	―	-78.55%	7.74%
IVA	41 Neutral	$616.04M	-0.99	―	―	-12.52%	-82.84%

Vir Biotechnology Corporate Events

Vir Biotechnology Reports Q3 2025 Financial Results and Clinical Progress

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for serious infectious diseases and cancer, leveraging its expertise in the immune system and innovative technologies like the PRO-XTEN masking platform.

Vir Biotechnology’s Innovative HDV Study: A Potential Game-Changer in Viral Treatment

Study Overview: Vir Biotechnology, Inc. is conducting a Phase 2b study titled ‘A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)’. The study aims to assess the efficacy and safety of a new combination therapy for chronic Hepatitis D Virus (HDV) infection, a significant health concern due to its severe liver complications.

Vir Biotechnology’s Promising Phase 3 Study for Chronic HDV Treatment

Vir Biotechnology, Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)’. The study aims to assess the effectiveness and safety of a combination therapy for patients with chronic hepatitis D virus (HDV) infection who have not responded to bulevirtide treatment.

Vir Biotechnology’s Phase 3 Study on HDV Treatment: A Potential Game-Changer?

Study Overview: Vir Biotechnology, Inc. is conducting a Phase 3 study titled A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1). The study aims to assess the effectiveness and safety of the combination therapy for treating chronic hepatitis delta, a significant health concern due to its severe liver complications.

Vir Biotechnology’s Innovative Approach in HER2-Expressing Cancer Treatment: A Study Update

Study Overview: Vir Biotechnology, Inc. is conducting a Phase 1 clinical study titled A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers. The study aims to assess the safety, pharmacokinetics, and preliminary activity of VIR-5818, both alone and combined with pembrolizumab, in treating HER2+ tumors. This research is significant as it explores new treatment avenues for challenging cancer types.

Vir Biotechnology’s Promising Prostate Cancer Study: A Potential Game-Changer?

Vir Biotechnology, Inc. is conducting a Phase 1 study titled A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer. The study aims to evaluate the safety and efficacy of VIR-5500 in treating hormone-refractory prostate cancer, a significant step in addressing this challenging condition.

Vir Biotechnology’s Phase 1 Study on VIR-5525: A Potential Game-Changer in Cancer Treatment?

Study Overview: Vir Biotechnology, Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5525 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors.’ The study aims to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of VIR-5525, both as a standalone treatment and in combination with pembrolizumab, for patients with EGFR-positive solid tumors.

Vir Biotechnology’s Hepatic Impairment Study: A Potential Game Changer?

Vir Biotechnology, Inc. is conducting a Phase 1 study titled Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434. The study aims to evaluate the pharmacokinetics, safety, and tolerability of VIR-2218 and VIR-3434, both as monotherapies and in combination, in adults with varying degrees of hepatic impairment, including cirrhosis. This research is significant as it seeks to understand how these drugs behave in patients with liver conditions, potentially informing future treatments.

Vir Biotechnology’s Earnings Call Highlights Progress and Challenges

Vir Biotechnology’s recent earnings call presented a balanced sentiment, highlighting significant progress in their clinical programs and financial management. Despite operating at a loss and experiencing substantial cash consumption, the company showcased advancements in its hepatitis delta and oncology programs, alongside improvements in cost efficiency, contributing to an optimistic outlook.

Vir Biotechnology Reports Q2 2025 Financial Results

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for serious infectious diseases and cancer, with a unique emphasis on leveraging the immune system to transform lives.